Image Source: AsiaOne
Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA NephropathyGlobeNewswireDecember 01, 2020SHANGHAI, China, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designation (BTD) for Nefecon for the treatment of IgA nephropathy (IgAN).
Source: AsiaOne